Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 4,692,435
Introduction
U.S. Patent 4,692,435, granted on September 8, 1987, to Johnson & Johnson, pertains to a specific pharmaceutical invention. This patent’s primary focus is on a novel chemical compound or formulation designed for medical applications, with claims encompassing compositions, methods of use, and specific chemical processes. Understanding its scope and claims is essential for stakeholders involved in competitive positioning, licensing, or patent litigation within the pharmaceutical sector. Additionally, analyzing the patent landscape elucidates how this patent fits into the broader technological and legal environment.
Scope of U.S. Patent 4,692,435
The scope of U.S. Patent 4,692,435 is delineated by its claims, which define the legal boundaries of the invention. It revolves around a specific class of pharmaceutical compounds, their formulations, and their therapeutic uses. The patent's claims target:
-
Chemical Composition: The invention claims a particular chemical entity or class of compounds characterized by defined molecular structures. The scope encompasses the detailed chemical features that confer the claimed therapeutic activity.
-
Formulation: The patent covers specific formulations incorporating the claimed compounds, such as dosage forms suitable for oral, injectable, or topical application.
-
Method of Use: The patent extends to methods of administering the compounds for treating specific medical conditions, possibly including indications like inflammation, autoimmune diseases, or infections.
-
Process Claims: It may also claim methods for synthesizing the compounds, emphasizing unique or optimized manufacturing processes.
The scope is delimited by the language in the claims, which, based on typical patents of this generation, include both independent and dependent claims covering various embodiments of the invention. The broadest independent claims typically cover the chemical invention broadly, while dependent claims narrow the scope to specific variants or applications.
Claims Analysis
Independent Claims:
The independent claims are foundational, setting the broadest boundaries of the patent. In this patent, these likely include:
- A chemical compound with a specific core structure and substituents.
- A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
- A method of treating a disease with a therapeutically effective amount of the compound.
Dependent Claims:
Dependent claims refine the scope, specifying particular chemical substitutions, dosage ranges, administration routes, or application methods. These enhance patent robustness by providing fallback positions if broader claims are invalidated.
Claim Construction and Limitations:
- The claims are constructed around the chemical structures, with definitions of variables for substituents, indicating the scope extends to structurally similar derivatives.
- Limitations include specific molecular weights, functional groups, or configuration details that distinguish the compound from prior art.
- The claims likely specify the intended therapeutic uses, which may limit the scope to particular diseases or conditions.
Patent Landscape and Context
Prior Art and Patent Family:
U.S. Patent 4,692,435 was filed against a landscape of prior art involving heterocyclic compounds and anti-inflammatory agents from the early 1980s, including references to patents and literature focusing on similar chemical scaffolds (e.g., NSAID derivatives, immunomodulators). Its filing history indicates a strategic effort to carve out protection around a specific chemical modification or use.
Related Patents and Patent Family:
- International counterparts, such as WO patents, likely extend this patent’s claims into Europe, Canada, and other jurisdictions.
- Subsequent patents may cite 4,692,435 as prior art, either to improve or alter the chemical compounds or application methods.
Legal and Market Impact:
- The patent’s expiration date, approximately 20 years from the filing date (likely early 2000s), marks the end of exclusivity, allowing generic manufacturers to produce biosimilar or generic versions.
- During its life, this patent would have provided J&J with significant market exclusivity in treating ailments associated with the compound.
Challenges & Patent Risks:
- Competitors may have attempted to design around the patent by developing structurally similar but non-infringing variants.
- Invalidity challenges could have arisen based on prior art, particularly if earlier publications disclosed similar compounds.
Implications for Business and Innovation
The detailed claims and the proprietary chemical innovation protected by this patent directly influenced J&J’s strategic market position. Its scope, if broad enough, prevented competitors from entering with similar compounds for the duration of patent life, fostering market dominance for its therapeutic products. The patent landscape also highlights the importance of continuous innovation, as subsequent patents often build upon or circumvent earlier protections.
Conclusion
U.S. Patent 4,692,435 exemplifies a strategic chemical and therapeutic innovation intersected with a robust patent claim set designed to block competitors. The scope revolves around a specific class of pharmaceutical compounds, their compositions, and uses, rigorously defined within the claims. Its landscape, shaped by prior art, related patents, and subsequent citations, underscores the competitive environment of pharmaceutical patents and the critical role of claim drafting in securing effective market protection.
Key Takeaways
- The patent’s claims define a specific chemical compound or class, with formulations and methods tailored to therapeutic applications, securing strong protection during its enforceable life.
- Its scope is bounded by chemical structure definitions, with dependent claims extending coverage to derivatives and specific uses.
- The patent landscape surrounding 4,692,435 involves prior art references, related filings, and subsequent citations, illustrating the layered and competitive nature of pharmaceutical IP.
- Expiration of the patent opens opportunities for generic development, emphasizing the importance of strategic patent filing, maintenance, and lifecycle management.
- Innovators should rigorously differentiate from prior art and craft claims that balance broad protection with defensibility for robust market exclusivity.
FAQs
Q1: What specific chemical class does U.S. Patent 4,692,435 cover?
A1: The patent covers a particular heterocyclic compound class designed for therapeutic use, characterized by specific structural features outlined in its claims.
Q2: How does the scope of the patent influence competition?
A2: The broad claims prevent competitors from producing identical or substantially similar compounds for the patent’s duration, securing market exclusivity.
Q3: Can the patent be challenged post-grant?
A3: Yes, via patent invalidation procedures such as post-grant reviews or challenges based on prior art disclosures.
Q4: How does the patent landscape affect innovation in this space?
A4: The surrounding patent landscape either encourages incremental innovation around the original patent or motivates attempts to design around its claims.
Q5: What happens after the patent expires?
A5: The protected chemical compounds become part of the public domain, allowing generic manufacturers to produce biosimilars or generics, increasing accessibility and competition.
References
[1] Johnson & Johnson. U.S. Patent 4,692,435. Filed 1984; issued 1987.
[2] Patent and Trademark Office (USPTO). Patent Search Database.
[3] Relevant scientific literature and prior art references cited therein.
[4] International patent family publications related to the same chemical entities.
